Novavax

Novavax, the Maryland-based vaccine maker, is seeing renewed interest in its shares, with its stock quote, price history and latest news being tracked by investors on finance platforms. The company, known for its COVID-19 vaccine, remains a focus for traders watching biotech and pandemic-related stocks, though no specific new development is detailed in the coverage.

A person who received the Novavax COVID-19 vaccine reported no side effects 22 hours after the shot, apart from soreness at the injection site, which they described as slightly worse than the flu jab they received at the same time. They noted that mRNA vaccines usually left them fatigued and chilled for an evening. The account adds to ongoing personal comparisons of protein-based versus mRNA vaccine side effects.